Nafeh, Frishta
Mbichila, Tinkhani
Bouck, Zachary
Scheim, Ayden
Mitra, Sanjana
Bonn, Matthew
Morris, Franky
Atkinson, Kate
Mason, Kate
Eeuwes, Jolene
Strike, Carol
Gomes, Tara
Werb, Dan
Karamouzian, Mohammad http://orcid.org/0000-0002-5631-4469
Funding for this research was provided by:
Canadian Institutes of Health Research (EV1-174804)
Article History
Accepted: 1 December 2023
First Online: 22 December 2023
Declarations
:
: Before starting the interview, participants were briefed about the study’s objectives and procedures. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975. Interviews were conducted in a private room, and data were collected anonymously to ensure confidentiality. Participants’ refusal to participate in the study did not in any way or form impact their access to healthcare services. The study was approved by the Research Ethics Boards at Unity Health Toronto (REB 21-273).
: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: KM is employed by one of the health centres where the pilot programs under evaluation took place. KA is employed in one of the pilot programs under evaluation. MB reports personal fees from AbbVie and grants and personal fees from Gilead Sciences, outside of the submitted work. MB has also worked for the Canadian Association of People Who Use Drugs which receives funds from Health Canada. Other authors declare no have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
: Written informed consent was obtained from all patients for being included in the study.